Vaccine for children under 5 delayed so FDA can review data on 3rd dose

by | Feb 17, 2022 | Coronavirus, Newborn Care, News, Wellness Care

The Food and Drug Administration (FDA) on Friday postponed a Feb. 15 meeting of its Vaccines and Related Biological Products Advisory Committee to discuss the Pfizer-BioNTech COVID-19 vaccine for children ages 6 months to 5 years and said the meeting likely will occur later this spring.   

FDA officials said the delay will allow more time to review data on a third dose and help decide whether three doses should be considered as part of its decision on emergency use authorization (EUA).

Read Full Article Here

Give Us A Call